Abstract:We read the study by Durila et al 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar with interest; however, we seek several clarifications. First, a separate study by Yu et al 2 Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk [e-pub ahead of print]. Korean J Intern Med. doi:10.3904/kjim.2019.112, accessed September 9, 2020. Google Scholar showed that the results of platelet function analyzer 200 (PFA 200) are influenced by various factors, such as the use of aspirin and other non-steroidal anti-inflammatory agents, blood group type, hematocrit and time of blood collection, transfusions, and underlying diseases. The severity of surgery might cause bleeding, which affects collagen–epinephrine and collagen–adenosine diphosphate. The conclusion that the pathology of primary hemostasis detected by the PFA 200 (collagen–epinephrine and collagen–adenosine diphosphate) was specific for the extracorporeal membrane oxygenation (ECMO) phase of surgery is not robust and is subject to confounding bias. 3 Zhang Z Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016; 4: 111 Crossref PubMed Scopus (192) Google Scholar Second, a continuous intravenous infusion of low-molecular-weight heparin was used to prevent venous thromboprophylaxis, but without dose described. Piwowarczyk et al 4 Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study [e-pub ahead of print]. ASAIO J. doi:10.1097/MAT.0000000000001166, accessed September 9, 2020. Google Scholar compared nadroparin with unfractionated heparin during veno-venous ECMO and found no significant difference in the number of thrombotic and hemorrhagic events. In the paper by Durila et al, 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar even with the use of continuous intravenous infusion of low-molecular-weight heparin, 2 patients suffered thrombotic events. Third, the duration of the ECMO in their work is short (5 ± 3 days). The effect of duration of support on outcomes was not provided because we would suggest that the risk of thrombotic events is lower with a shorter duration of ECMO support. Given these considerations, it is difficult for us to completely agree with the conclusion that the PFA 200 analyzer may be used to prevent circuit thrombosis instead of using unfractionated heparin in patients on prolonged ECMO. We believe that a point-of-care test such as the PFA 200 may assist in adjusting anti-coagulant strategy to potentially reduce the use of unfractionated heparin rather than to prevent circuit thrombosis and obviate the use of unfractionated heparin altogether, especially in patients on prolonged ECMO support.

[Non-imported conjunctivitis with detection of Chlamydia trachomatis].

Research and human subjects.

Discordance among assays for monitoring? Anticoagulation during extracorporeal life support

Evaluation of an aPTT guided versus a multimodal heparin monitoring approach in patients on extra corporeal membrane oxygenation: A retrospective cohort study

Anti-Xa-guided anticoagulation with unfractionated heparin and thrombosis during ECMO support: A systematic review and meta-analysis

Parameter estimation of hydrologic models using a likelihood function for censored and binary observations.

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?

Outcomes of heparinized adult veno-arterial extracorporeal membrane oxygenation patients managed with low and high activated partial thromboplastin time targets: A systematic review and meta-analysis

Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Prevalence of FXII-Deficiency and Its Relevance to Monitoring Anticoagulation in Adults Receiving Extracorporeal Membrane Oxygenation

Antimicrobial therapy of experimental intraabdominal sepsis.

A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy

Association of anti‐factor Xa‐guided anticoagulation with hemorrhage during ECMO support: A systematic review and meta‐analysis

Antithrombin levels and heparin responsiveness during veno-arterial extracorporeal membrane oxygenation: a prospective single-center cohort study

Evaluation of a Multimodal Heparin Laboratory Monitoring Protocol in Adult Extracorporeal Membrane Oxygenation Patients

Discordance between aPTT and anti‐Xa in monitoring heparin anticoagulation in mechanical circulatory support

Association of aPTT-Guided Anticoagulation Monitoring with Thromboembolic Events in Patients Receiving V-A ECMO Support: A Systematic Review and Meta-Analysis

Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

Dual guided heparin monitoring with anti-Xa and APTT during micro-axial flow pump support for cardiogenic shock

Investigating the Complexity of Organizational Digitization and Firm Performance: A Set-Theoretic Configurational Approach

Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO